With a screening programme to identify a group of mothers at increased risk of a pregnancy with Down's syndrome, it is possible to calculate individual risks or absolute probabilities on which decisions for or against further diagnostic procedures can be based. The absolute probability of an individual woman with known maternal serum a fetoprotein concentration and age at expected date of delivery can be calculated by the method described by Dennis and Carter for overlapping normal distributions.7 Figure 3 shows the probability of a mother carrying a baby with Down's syndrome with maternal serum u fetoprotein concentration between 013 and 1-5 multiples of the median where the probability of carrying a baby with Down's syndrome is one using the distributions shown in table II. Figure 4 shows the absolute probability of carrying a baby with Down's syndrome calculated for individual values of maternal serum (a fetoprotein by maternal age.
We therefore suggest that maternal serum a fetoprotein concentration equal to or less than the sliding scale described by Cuckle et al2 should be used as a screening test to identify women whose collective risk of having a baby with Down's syndrome is greater than one in 200, and these will be the women aged 32 and over. The accuracy of the information on the high risk group could then be improved by repeat maternal serum a fetoprotein screening and scan. Their absolute probability of carrying a baby with Down's syndrome could then be calculated using the aforementioned probability at the individual maternal age and an informed decision about further diagnostic tests could be based on a known risk of carrying a baby with Down's syndrome, the views of the parents, and the risks of the procedure. 
Present study
Wearing gowns, gloves, and goggles, whether or not a vertical laminar flow cabinet is used, seem appropriate and useful measures when handling cytotoxic agents. Prudent management of spillage and excreta is indicated, and incineration of such materials at as high a temperature as possible also seems useful. Many different institutions and authorities have prepared guidelines and made practical suggestions concerning the preparation, administration, and disposal of cytotoxic agents. 2 4 Presumably the pharmaceutical companies have informatioon and interest in such safeguards and might pass on information to users. Certainly their drug package inserts are informative on chemical constitution, physical properties, indications for usage, dosage, contraindications, and advice on dealing with adverse reactions in patients. Twenty four such inserts relating to the 21 most commonly used agents (table) were inspected. Nine intimated that the drugs were irritant to skin and mucous membranes, but only four recommended wearing gloves and only three mentioned eye hazards. Preparation of drugs in a vertical laminar flow safety cabinet, which is recommended by many4 but not all authorities, was not mentioned in any case.
The question of disposal of residue, waste, and spillage is a vexed one and advice of the manufacturers has been sought in the past. Evidently the general opinion was that flushing the drug residue through the drainage system with copious amounts of water was adequate,3 but this was not reiterated in any drug insert inspected. Other experts have suggested that solid waste materials should be buried or incinerated at around 1000°C,5 but only two inserts touched on this subject.
There is a possibility that patients receiving cytotoxic agents may excrete appreciable amounts of these drugs and that their excreta may be hazardous. Whether this is true in the usual case is doubtful but it may be so in those given very high doses and those receiving treatment by bladder instillation. This particular problem is not covered in the world publications at large or in any company packaging literature. 
Comment
It is certainly true that the clinical responsibilities associated with the use of cytotoxic agents lie with the prescribers-the oncologists. This is accepted. But would it not be appropriate for those who manufacture these agents to assume some responsibility? Should not the pharmaceutical companies who provide these agents offer practical advice on preparation and disposal problems? These companies presumably have access to the requisite scientific data and probably utilise them in the manufacturing and packaging processes. Might they not disseminate this information so that the pharmacists, nurses, and doctors at risk could make appropriate adjustments in their clinical practice? The drug packaging inserts would be an obvious place for this advice. Renal disease and digoxin immunoassays 
Subjects, methods, and results
We studied 26 patients receiving renal dialysis (16 from the Netherlands, 10 from Northern Ireland). Blood samples were taken before dialysis and the separated serum assayed for creatinine and digoxia concentrations using assays routinely employed in the respective hospital laboratories. At the time of the study none of the patients was receiving digoxin. The table shows the age and sex of the patients and their serum creatinine concentrations. When analyses were complete at one centre the samples were exchanged and reassayed at the other centre. The methods used included two radioimmunoassay techniques (Amerlex, Amersham International, England; DPC, the Netherlands), a fluorometric enzyme immunoassay (Stratus, USA), and a fluorescence polarisation immunoassay (Abbott Diagnostics, USA). The samples from the Netherlands (cases 1-16) were also assayed using fluorescence energy transfer immunoassay (Syva, USA). With the exception of the fluorescence polarisation technique, which was used in the liver disease report,' none of the methods had been tested for cross reactivity with endogenous immunoreactive substances in serum. In all cases the assay techniques yielded negative digoxin values (detection limit 256 pmol/l (0-2 ng/ml)).
Data on patients whose serum was assayed for digoxin like immunoreactive substance using range of immunoassay techniques. 
